DK1162272T3 - Frembringelse af immunreaktioner med prostataspecifikt antigen (SPA) - Google Patents

Frembringelse af immunreaktioner med prostataspecifikt antigen (SPA)

Info

Publication number
DK1162272T3
DK1162272T3 DK01113517T DK01113517T DK1162272T3 DK 1162272 T3 DK1162272 T3 DK 1162272T3 DK 01113517 T DK01113517 T DK 01113517T DK 01113517 T DK01113517 T DK 01113517T DK 1162272 T3 DK1162272 T3 DK 1162272T3
Authority
DK
Denmark
Prior art keywords
psa
host
virus vector
specific antigen
additional
Prior art date
Application number
DK01113517T
Other languages
English (en)
Inventor
Jeffrey Schlom
Dennis Panicali
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23988841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1162272(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK1162272T3 publication Critical patent/DK1162272T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
DK01113517T 1995-07-10 1996-06-26 Frembringelse af immunreaktioner med prostataspecifikt antigen (SPA) DK1162272T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/500,306 US6165460A (en) 1995-07-10 1995-07-10 Generation of immune responses to prostate-specific antigen (PSA)
PCT/US1996/010837 WO1997003203A2 (en) 1995-07-10 1996-06-26 Generation of immune responses to prostate-specific antigen (psa)

Publications (1)

Publication Number Publication Date
DK1162272T3 true DK1162272T3 (da) 2009-03-09

Family

ID=23988841

Family Applications (2)

Application Number Title Priority Date Filing Date
DK96923417T DK0840791T3 (da) 1995-07-10 1996-06-26 Frembringelse af immunreaktioner mod prostataspecifikt antigen (PSA)
DK01113517T DK1162272T3 (da) 1995-07-10 1996-06-26 Frembringelse af immunreaktioner med prostataspecifikt antigen (SPA)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK96923417T DK0840791T3 (da) 1995-07-10 1996-06-26 Frembringelse af immunreaktioner mod prostataspecifikt antigen (PSA)

Country Status (11)

Country Link
US (2) US6165460A (da)
EP (2) EP1162272B8 (da)
JP (3) JP4633867B2 (da)
AT (2) ATE413459T1 (da)
CA (1) CA2226436C (da)
DE (2) DE69618601T2 (da)
DK (2) DK0840791T3 (da)
ES (2) ES2320089T3 (da)
HK (1) HK1042518B (da)
PT (2) PT840791E (da)
WO (1) WO1997003203A2 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699475B1 (en) * 1987-09-02 2004-03-02 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
US6946133B1 (en) * 1996-03-20 2005-09-20 The United States Of America As Represented By The Department Of Health And Human Services Prostate specific antigen oligo-epitope peptide
US20010036928A1 (en) * 1996-04-22 2001-11-01 Chamberlain Ronald S. Heterologous boosting immunizations
EP0954593A1 (en) * 1996-07-25 1999-11-10 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
EP1497320B1 (en) 2001-11-14 2011-08-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES New gene expressed in prostate cancer and methods of use
BR0311720A (pt) * 2002-06-11 2005-03-01 Merck Patent Gmbh Método para mapear e eliminar epitopos de células t
DE10230893A1 (de) * 2002-06-26 2004-01-15 Dr. Fischer Ag Verfahren zur Eigenschaftsbestimmung und/oder Klassifikation von zirkulierenden Macrophagen und/oder peripheren blutmononuclearen Zellen sowie Analyseanordnung zur Durchführung des Verfahrens
WO2004056977A1 (en) * 2002-12-13 2004-07-08 Aventis Pasteur, Inc. Production of alvac on avian embryonic stem cells
WO2005005465A2 (en) * 2003-07-08 2005-01-20 Board Of Regents, University Of Texas System Methods and compositions to enhance immune responses via recall antigens
NZ545438A (en) * 2003-08-21 2008-08-29 Virax Dev Pty Ltd Poxvirus vector encoding prostate specific antigens for treatment of prostate cancer
CA2570563A1 (en) * 2004-06-15 2006-09-28 Centocor, Inc. Method for screening agents against human prostate disease
CA2612225A1 (en) * 2005-06-21 2007-01-04 Cyto Pulse Sciences, Inc. Methods and compositions relating to a vaccine against prostate cancer
EP1994409A2 (en) 2006-03-14 2008-11-26 Oregon Health and Science University Methods for producing an immune response to tuberculosis
NZ704295A (en) 2006-12-27 2016-06-24 Harvard College Compositions and methods for the treatment of infections and tumors
AU2008221383B2 (en) 2007-02-28 2012-09-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
RU2499606C2 (ru) * 2007-10-18 2013-11-27 Бавэариан Нордик Инк. Применение mva (модифицированный вирус коровьей оспы анкара) для лечения рака простаты
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
WO2010050913A1 (en) * 2008-10-31 2010-05-06 The Brigham And Women's Hospital, Inc. Vaccination with poxvirus vectors via mechanical epidermal disruption
AU2009319701B2 (en) 2008-11-28 2014-10-09 Dana-Farber Cancer Institute, Inc. Methods for the treatment of infections and tumors
US8664183B2 (en) 2009-02-27 2014-03-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SPANX-B polypeptides and their use
US8961989B2 (en) 2009-11-20 2015-02-24 Oregon Health & Science University Methods for producing an immune response to tuberculosis
US9804163B2 (en) 2010-08-06 2017-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for prostate cancer and methods for their detection
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
JPWO2014097762A1 (ja) * 2012-12-20 2017-01-12 国立大学法人 熊本大学 高病原性トリインフルエンザに対する抗体
WO2015175340A1 (en) 2014-05-13 2015-11-19 Bavarian Nordic, Inc. Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3
JP5917626B2 (ja) * 2014-07-28 2016-05-18 トレムアールエックス， インコーポレイテッド 機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種
CN107849117B (zh) 2015-06-05 2022-08-26 艾比欧公司 用于治疗纤维化的内皮抑素片段和变体
US10550164B2 (en) 2015-08-03 2020-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury deletion mutants, non-yeast vectors encoding Brachyury deletion mutants, and their use
US20190183870A1 (en) 2016-01-05 2019-06-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
WO1989001973A2 (en) * 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
US5093258A (en) * 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
ES2206446T3 (es) * 1991-05-06 2004-05-16 The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services Virus recombinante que expresa un antigeno carcinoembrionico y metodos de uso del mismo.
ES2276390T3 (es) * 1992-11-05 2007-06-16 Sloan-Kettering Institute For Cancer Research Antigeno de membrana especifico de la prostata.
DE69434475T2 (de) * 1993-08-11 2006-05-18 Jenner Technologies, Tiburon Impfstoff gegen prostatakrebs
FR2710536B1 (fr) * 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
EP0652014A1 (en) * 1993-11-10 1995-05-10 National Institute Of Immunology Treatment of prostatic hypertrophy
ZA941645B (en) * 1994-03-09 1995-01-13 South To South Co Operation In Antibodies specifically reactive against human prostate specific antigen.
EP0725139A3 (en) * 1995-02-03 1997-11-26 Bayer Corporation Recombinant prostate-specific antigen and its use as an immunoassay calibrator
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)

Also Published As

Publication number Publication date
US7598225B1 (en) 2009-10-06
ES2172669T3 (es) 2002-10-01
ATE212058T1 (de) 2002-02-15
PT840791E (pt) 2002-06-28
US6165460A (en) 2000-12-26
EP1162272A3 (en) 2004-07-14
JP2006197938A (ja) 2006-08-03
EP0840791B1 (en) 2002-01-16
CA2226436A1 (en) 1997-01-30
DE69618601D1 (de) 2002-02-21
HK1042518B (zh) 2009-04-17
CA2226436C (en) 2006-11-07
DE69618601T2 (de) 2002-08-08
JPH11509199A (ja) 1999-08-17
HK1042518A1 (en) 2002-08-16
EP0840791A2 (en) 1998-05-13
DE69637738D1 (de) 2008-12-18
WO1997003203A3 (en) 1997-04-17
ATE413459T1 (de) 2008-11-15
EP1162272B1 (en) 2008-11-05
EP1162272A2 (en) 2001-12-12
JP2008285492A (ja) 2008-11-27
WO1997003203A2 (en) 1997-01-30
JP4633867B2 (ja) 2011-02-16
EP1162272B8 (en) 2010-03-10
ES2320089T3 (es) 2009-05-19
PT1162272E (pt) 2009-02-16
DK0840791T3 (da) 2002-03-18

Similar Documents

Publication Publication Date Title
DK1162272T3 (da) Frembringelse af immunreaktioner med prostataspecifikt antigen (SPA)
DK1227837T3 (da) Fremgangsmåde til introduktion og/eller fremskyndelse af et immunrespons på et tumorantigen
DE69739253D1 (de) Liposomaler grippeimpfstoff und verfahren
BR9608615A (pt) Vacinas de vírus sincicial respiratório de ácido nucléico
ATE391783T1 (de) Verfahren und reagenzien zur erzeugung einer cd8+ t-zellen immunantwort gegen melanoma
DE69536091D1 (de) Immunisierung durch Impfung von DNS Transkriptionseinheit
NO963508L (no) Urease-basert vaksine og behandling av Helicobacter-infeksjon
DK0724642T3 (da) Nukleinsyrevektor, sammensætning indeholdende en sådan vektor og vaccine til immunisering mod hepatitis
ATE395932T1 (de) Rekombinanter immunschwächepoxvirus
NO924780L (no) Ekspresjon av spesifikke immunogener ved bruk av virusantigener
GB0118532D0 (en) Materials and methods relating to improved vaccination strategies
WO1999002132A3 (en) Use of submicron oil-in-water emulsions with dna vaccines
DK0728015T3 (da) Kombinatoriske polypeptidantigener
DE69937258D1 (de) Genetische impstoffe mit adjuvans
KR890000106A (ko) 원생성 기생충 예방용 백신
DK0729509T3 (da) Vaccine imod fåresyge indeholdende en Jeryl-Lynn virus-stamme
EP0476059A4 (en) Methods for enhancing the rate of modification of metastable bonds
ATE460945T1 (de) Genetische adjuvanz-impfstoffe
MX9709525A (es) Vacunas de virus sincicial respiratorio de acido nucleico.